title: [Nobel price for vaccination against cervical cancer: current data and guidelines].
abstract: Harald zur Hausen received the Nobel price for Medicine in 2008 for his seminal research on human papilloma viruses and their association with anogenital diseases. On the basis of his work highly effective prophylactic vaccines have been developed. Clinical studies have shown nearly 100% seroconversion and an excellent safety profile as well as greater than 96% efficacy against HPV infection and premalignant dysplasia, induced by HPV types covered by the vaccine. Due to the convincing data of phase II and III clinical trials the introduction of HPV vaccination was recommended by health authorities and scientific committees in Germany. The development and availability of guidelines and evidence-based recommendations should support the introduction of the vaccine and widespread vaccination.
authors.affiliation: Gynäkologische Tumorimmunologie, Klinik für Gynäkologie, Charité, Campus Benjamin Franklin, Berlin.
authors.forename: H M
authors.initials: HM
authors.lastname: Hepburn
authors.forename: A M
authors.initials: AM
authors.lastname: Kaufmann
mesh_terms: D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000592:standards*; D005260:Female; D006801:Humans; D038622:Internationality; D008495:Medical Oncology / Q000592:standards*; D009613:Nobel Prize; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000592:standards*; D017410:Practice Guidelines as Topic; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control*
chemical_list: D019496:Cancer Vaccines; D053918:Papillomavirus Vaccines